New research presented at the 63rd ERA Congress suggests that a widely used class of blood pressure medications may be ...
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report outlays ...
In addition to AIS, DiaMedica (DMA.V) (DMCAF) is also developing DM199 for the treatment of diabetic kidney disease (DKD). Diabetic kidney disease (DKD) or Diabetic nephropathy (DN) is one of the most ...
Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial. C. Ola Landgren, MD, PhD: The once-weekly and twice-weekly ...
George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease. Neil B. Minkoff, MD: Dr Bakris, I ...
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of ...
In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the ...
Evidence of a substantial heritability of diabetic kidney disease (DKD) exists but the genetic background is poorly understood. New data confirm that renal complications in type 1 diabetes mellitus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results